CAR T Referral Process: Insights From Kansas

Al-Ola Abdallah, MD; Muhammad Umair Mushtaq, MD; Jeries Kort, MD; and Zahra Mahmoudjafari examine the evolving landscape of chimeric antigen receptor (CAR) T-cell therapy in earlier lines of treatment for relapsed/refractory multiple myeloma, exploring institutional challenges around patient selection, slot availability, referral processes, and decision-making frameworks while considering both clinical and practical factors that influence treatment sequencing and access.